The claims covers the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Alan Moore, president and CEO of SCT, said: “The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT’s overall intellectual property portfolio.”
SCT’s patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.